Rivaroxaban versus warfarin: differential effects on oxidative stress and fibrinolytic markers in atrial fibrillation.

Reis HJ, Costa LBX, Martins GL, Duarte RCF, Costa LCM, Figueiredo EL, Silveira FR, Coelho NG, Carvalho MDG, Vieira LB, Reis EA, Gomes KB, Ferreira CN

Open source

DOI: 10.3389/fphar.2026.1685101
Published: 2026
Container: Frontiers in pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1685101,
  title = {Rivaroxaban versus warfarin: differential effects on oxidative stress and fibrinolytic markers in atrial fibrillation.},
  author = {Reis HJ and Costa LBX and Martins GL and Duarte RCF and Costa LCM and Figueiredo EL and Silveira FR and Coelho NG and Carvalho MDG and Vieira LB and Reis EA and Gomes KB and Ferreira CN},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1685101},
  url = {https://doi.org/10.3389/fphar.2026.1685101}
}

RIS

TY  - JOUR
TI  - Rivaroxaban versus warfarin: differential effects on oxidative stress and fibrinolytic markers in atrial fibrillation.
AU  - Reis HJ
AU  - Costa LBX
AU  - Martins GL
AU  - Duarte RCF
AU  - Costa LCM
AU  - Figueiredo EL
AU  - Silveira FR
AU  - Coelho NG
AU  - Carvalho MDG
AU  - Vieira LB
AU  - Reis EA
AU  - Gomes KB
AU  - Ferreira CN
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1685101
UR  - https://doi.org/10.3389/fphar.2026.1685101
ER  -

APA

HJ, R., LBX, C., GL, M., RCF, D., LCM, C., EL, F., FR, S., NG, C., MDG, C., LB, V., EA, R., KB, G., & CN, F. (2026). Rivaroxaban versus warfarin: differential effects on oxidative stress and fibrinolytic markers in atrial fibrillation.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1685101

Source records

pubmed · retrieved 2026-09-25T13:10:54.345Z